Effects of Early Post-Ischemic Reperfusion and tPA on Cerebrovascular Function and Nitrosative Stress in Female Rats

Translational Stroke Research

Volumn 7, Issue 3, 2016, Pages 228-238

  Ahnstedt, Hilda ^a   Sweet, Julie ^a   Cruden, Patrick ^a   Bishop, Nicole ^a   Cipolla, Marilyn J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

3 Nitrotyrosine; Cerebral ischemia; Middle cerebral arteries; Myogenic tone; Parenchymal arterioles; Reperfusion

Indexed keywords

3 NITROTYROSINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; F ACTIN; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; RHO KINASE; TISSUE PLASMINOGEN ACTIVATOR; 3-NITROTYROSINE; ACTIN; AMIDE; ENZYME INHIBITOR; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; COLLATERAL CIRCULATION; CONTROLLED STUDY; FEMALE; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUTROPHIL; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN CIRCULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; MIDDLE CEREBRAL ARTERY; OVARIECTOMY; PATHOLOGY; REPERFUSION; SMOOTH MUSCLE; WISTAR RAT;

ACTINS; AMIDES; ANIMALS; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY; MUSCLE, SMOOTH; NEUTROPHILS; OVARIECTOMY; PYRIDINES; RATS; RATS, WISTAR; REPERFUSION; REPERFUSION INJURY; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

EID: 84964461932     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0468-4     Document Type: Article

References (52)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
2. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke. 2009;40:1032–7.
3. Ullberg T, Zia E, Petersson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. Stroke. 2015;46:389–94.
4. Kunz A, Iadecola C. Cerebral vascular dysregulation in the ischemic brain. Handb Clin Neurol. 2009;92:283–305.
5. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–7.
6. Cipolla MJ, Curry AB. Middle cerebral artery function after stroke: the threshold duration of reperfusion for myogenic activity. Stroke. 2002;33:2094–9.
7. Cipolla MJ, Lessov N, Hammer ES, Curry AB. Threshold duration of ischemia for myogenic tone in middle cerebral arteries: effect on vascular smooth muscle actin. Stroke. 2001;32:1658–64.
8. Cipolla MJ, McCall AL, Lessov N, Porter JM. Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke. 1997;28:176–80.
9. Cipolla MJ, Chan SL, Sweet J, Tavares MJ, Gokina N, Brayden JE. Postischemic reperfusion causes smooth muscle calcium sensitization and vasoconstriction of parenchymal arterioles. Stroke. 2014;45:2425–30.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.
11. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.
12. De Silva DA, Fink JN, Christensen S, Ebinger M, Bladin C, Levi CR, et al. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke. 2009;40:2872–4.
13. Soares BP, Tong E, Hom J, Cheng SC, Bredno J, Boussel L, et al. Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. Stroke. 2010;41:e34–40.
14. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22:1276–83.
15. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol. 1994;144:188–99.
16. Grogaard B, Schurer L, Gerdin B, Arfors KE. Delayed hypoperfusion after incomplete forebrain ischemia in the rat. The role of polymorphonuclear leukocytes. J Cereb Blood Flow Metab. 1989;9:500–5.
17. Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke. 1986;17:246–53.
18. Mori E, del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke. 1992;23:712–8.
19. Carvalho-Tavares J, Hickey MJ, Hutchison J, Michaud J, Sutcliffe IT, Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res. 2000;87:1141–8.
20. Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab. 2015;35:888–901.
21. Lenglet S, Montecucco F, Denes A, Coutts G, Pinteaux E, Mach F, et al. Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice. J Cereb Blood Flow Metab. 2014;34:802–12.
22. Miyazaki T, Kimura Y, Ohata H, Hashimoto T, Shibata K, Hasumi K, et al. Distinct effects of tissue-type plasminogen activator and SMTP-7 on cerebrovascular inflammation following thrombolytic reperfusion. Stroke. 2011;42:1097–104.
23. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 2005;65:1169–74.
24. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke. 2005;36:1447–51.
25. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005;36:62–5.
26. Hill MD, Kent DM, Hinchey J, Rowley H, Buchan AM, Wechsler LR, et al. Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke. 2006;37:2322–5.
27. Buijs JE, Uyttenboogaart M, Brouns R, de Keyser J, Kamphuisen PW, Luijckx GJ. The effect of age and sex on clinical outcome after intravenous recombinant tissue plasminogen activator treatment in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2016;25:312–6.
28. Llull L, Laredo C, Renu A, Perez B, Vila E, Obach V, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke. 2015.
29. Lukic-Panin V, Deguchi K, Yamashita T, Shang J, Zhang X, Tian F, et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res. 2010;7:319–29.
30. Maneen MJ, Cipolla MJ. Peroxynitrite diminishes myogenic tone in cerebral arteries: role of nitrotyrosine and F-actin. Am J Physiol Heart Circ Physiol. 2007;292:H1042–50.
31. Cipolla MJ, Lessov N, Clark WM, Haley Jr EC. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke. 2000;31:940–5.
32. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8, e1000412.
33. Cipolla MJ, Sweet JG, Gokina NI, White SL, Nelson MT. Mechanisms of enhanced basal tone of brain parenchymal arterioles during early postischemic reperfusion: role of ET-1-induced peroxynitrite generation. J Cereb Blood Flow Metab. 2013;33:1486–92.
34. Koizumi J, Yoshida Y, Nakasawa T, Ooneda G. Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986;8:1–8.
35. Halpern W, Osol G, Coy GS. Mechanical behavior of pressurized in vitro prearteriolar vessels determined with a video system. Ann Biomed Eng. 1984;12:463–79.
36. Faraci FM, Baumbach GL, Heistad DD. Cerebral circulation: humoral regulation and effects of chronic hypertension. J Am Soc Nephrol. 1990;1:53–7.
37. Casella GT, Bunge MB, Wood PM. Improved immunocytochemical identification of neural, endothelial, and inflammatory cell types in paraffin-embedded injured adult rat spinal cord. J Neurosci Methods. 2004;139:1–11.
38. Cambj-Sapunar L, Yu M, Harder DR, Roman RJ. Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke. 2003;34:1269–75.
39. Cipolla MJ, Smith J, Kohlmeyer MM, Godfrey JA. SKCa and IKCa Channels, myogenic tone, and vasodilator responses in middle cerebral arteries and parenchymal arterioles: effect of ischemia and reperfusion. Stroke. 2009;40:1451–7.
40. Andresen J, Shafi NI, Bryan Jr RM. Endothelial influences on cerebrovascular tone. Br J Appl Phys (1985). 2006;100:318–27.
41. Gokina NI, Park KM, McElroy-Yaggy K, Osol G. Effects of Rho kinase inhibition on cerebral artery myogenic tone and reactivity. Br J Appl Phys (1985). 2005;98:1940–8.
42. Maeda Y, Hirano K, Nishimura J, Sasaki T, Kanaide H. Rho-kinase inhibitor inhibits both myosin phosphorylation-dependent and -independent enhancement of myofilament Ca2+ sensitivity in the bovine middle cerebral artery. Br J Pharmacol. 2003;140:871–80.
43. Moreno-Dominguez A, El-Yazbi AF, Zhu HL, Colinas O, Zhong XZ, Walsh EJ, et al. Cytoskeletal reorganization evoked by Rho-associated kinase- and protein kinase C-catalyzed phosphorylation of cofilin and heat shock protein 27, respectively, contributes to myogenic constriction of rat cerebral arteries. J Biol Chem. 2014;289:20939–52.
44. Maneen MJ, Hannah R, Vitullo L, DeLance N, Cipolla MJ. Peroxynitrite diminishes myogenic activity and is associated with decreased vascular smooth muscle F-actin in rat posterior cerebral arteries. Stroke. 2006;37:894–9.
45. Ritter LS, Orozco JA, Coull BM, McDonagh PF, Rosenblum WI. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke. 2000;31:1153–61.
46. Jimenez-Altayo F, Martin A, Rojas S, Justicia C, Briones AM, Giraldo J, et al. Transient middle cerebral artery occlusion causes different structural, mechanical, and myogenic alterations in normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;293:H628–35.
47. Jimenez-Altayo F, Caracuel L, Perez-Asensio FJ, Martinez-Revelles S, Messeguer A, Planas AM, et al. Participation of oxidative stress on rat middle cerebral artery changes induced by focal cerebral ischemia: beneficial effects of 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran (CR-6). J Pharmacol Exp Ther. 2009;331:429–36.
48. Onetti Y, Dantas AP, Perez B, Cugota R, Chamorro A, Planas AM, et al. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol. 2015;308:H862–74.
49. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561–5.
50. El Amki M, Lerouet D, Coqueran B, Curis E, Orset C, Vivien D, et al. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. Exp Neurol. 2012;238:138–44.
51. Haelewyn B, Risso JJ, Abraini JH. Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human’ dose for stroke studies in rats? J Cereb Blood Flow Metab. 2010;30:900–3.
52. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res. 1990;66:8–17.